Long Term Care Formulary HCD - 08
|
|
- Shauna Riley
- 6 years ago
- Views:
Transcription
1 1 of 5 PREAMBLE Opioids are an important component of the pharmaceutical armamentarium for management of chronic pain. The superiority of analgesic effect of one narcotic over another is not generally suggested by evidence; rather agents tend to be differentiated clinically in terms of tolerance and ability to obtain desired analgesia without undue adverse effects. Fentanyl is different from other long-acting opioids in it s mode of delivery. It is a significantly potent opioid and is best reserved for individuals who either need a topical delivery form or who have not achieved therapeutic goals with other opioid analgesics. It is not recommended for use in opioid-naïve individuals, or for individuals with a limited life expectancy of hours to days. Because of its potency, fentanyl is reserved for those individuals who have required at least 60 mg * of oral morphine equivalents on a daily basis for 1 week or longer. PROTOCOL Approved under the following conditions: 1. Residents with persistent, severe, chronic pain who require continuous around-the-clock analgesia for an extended period of time but who cannot swallow or who have a malabsorption syndrome leading to inability to benefit from long acting opioid preparations. 2. Residents with persistent, severe chronic pain who require continuous around-the-clock analgesia for an extended period of time and who require opioid therapy at a total daily dose of at least 60 mg/day oral morphine equivalents. Patients must have tried and failed with at least two discrete courses of therapy with two of the following agents: morphine, hydromorphone and oxycodone, if not contraindicated. A discrete course is defined as a separate treatment course, which may involve more than 1 agent, used at one time to manage the patient's condition. A failed opioid trial occurs when dosage titration to achieve pain control is not possible due to unacceptable side effects such as uncontrollable nausea & vomiting, distressing hallucinations, excessive sedation and severe cognitive impairment. 3. Residents admitted to a continuing care centre receiving opioid therapy covered by this protocol are eligible for continued use of the opioid upon review, unless a change is clinically indicated. 4. Residents residing in a continuing care centre and currently receiving opioid therapy covered by * Some centers have used 30mg oral morphine equivalents as a starting point, but that practice is not in the product monograph and so not recommended by the Long Term Care Pharmacy & Therapeutics Committee
2 2 of 5 this protocol are eligible for continued use of the opioid, unless a change is clinically indicated. 5. The patient s medication profile must be reviewed in full by a pharmacist, whenever a new prescription or dose change for fentanyl patch therapy is received. Patients awaiting transfer from a CHR acute care site to continuing care should have the drug use evaluated, when possible, prior to long term care placement for compliance with criterion 1 or 2. The findings of this evaluation should be communicated to the Long Term Care pharmacy provider by the acute care site to aid in the completion of the High Cost Drug (HCD-08) Funding Request Formfentanyl which would be completed and processed as per the HCD List Policy and Procedure. In the event that use does not comply with criterion 1 or 2, it is reasonable to convert topical fentanyl therapy to an alternate opioid (morphine, hydromorphone, or oxycodone) and route of administration. Notes: 1. The fentanyl patch is not appropriate for unstable pain where there is a requirement for titration to attempt to achieve pain control. Rapid titration is not recommended with fentanyl and should be avoided. When converting to fentanyl from an oral opioid, the dose and effects of an immediate release opioid need to be determined. Once determined, the total daily dose is then converted to an equivalent fentanyl dose based on manufacturer s conversion tables (see product monograph in the current CPS). The peak effect of the first dose takes hours to be seen. For this reason, overlap of fentanyl with the prior opioid is recommended for the first 12 hours. It is also recommended that the fentanyl patch dose not be titrated more frequently than every 3 days. 2. When switching fentanyl to an alternate oral opioid, it is advisable for the calculated equi-analgesic dose of the second agent to be reduced by 50-60%. Initially titration with an immediate release preparation on a regular scheduled basis with q2h prn for breakthrough pain is recommended. When rotating off the fentanyl patch, remove the patch and start the new opioid 12 hours later. Breakthrough medications should be available during this time and afterwards. 3. The duration of effect is usually 3 days though may vary in some individuals from hours. 4. The effects of the fentanyl patch can continue for 24 hours or more following removal, due to the effect of a subcutaneous depot of fentanyl. 5. It is recommended to use fentanyl patches cautiously when using them in combination with other opioid analgesics, CNS depressants or drugs that affect the metabolism of fentanyl (e.g.,cyp 3A4 inhibitors increase or prolong the effect of fentanyl [e.g., erythromycin, diltiazem, clarithromycin). 6. Application of a heat source to the patch (e.g., heating pad, hot packs), may result in increased release and absorption because of increased skin permeability. Fever may also enhance this effect.
3 3 of 5 7. It is recommended that the documentation process clearly communicates the date, time, and location of patch administered and the date, time, and location of patch to be removed (e.g. by providing prompts on the MAR). 8. It is recommended that an alert is provided on the MAR for patients receiving more than one medication via the transdermal route. PROCEDURE Compliance with the procedure outlined under HCD-02 (High Cost Drug Use Conditions) is necessary for drug cost reimbursement. REFERENCES ISMP Medication Safety Alert, Jun 28,2007 volume 12 Issue 13 ISMP Medication Safety Alert, August 14, 2006, Volume 6, Issue 5 Alberta Blue Cross Drug Benefit List, Duragesic coverage criteria Public advisory: Health Canada endorsed important safety information on Duragesic (fentanyl transdermal system). Ottawa (ON) Health Canada 2005 Sep 16 (cited 2007 Oct 1) Duragesic product monograph, Compendium of Pharmaceutical Specialties Alberta Palliative Care Resource Manual Alberta Cancer Board 2001 The following guidelines for switching to Transdermal (td) Fentanyl as outlined in the 2 nd edition of The Alberta Palliative Care Resource (2001). They have been edited to reflect the CPS 2007 Duragesic monograph. SWITCHING TO TRANSDERMAL (td) FENTANYL Step 1: Step 2: Step 3: CALCULATE THE TOTAL DAILY DOSE OF QUICK RELEASE OPIOID USE MANUFACTURER S CONVERSION TABLE TO CALCULATE THE EQUIVALENT DOSE OF TRANSDERMAL FENTANYL GIVE BREAKTHROUGH ORDERS Since fentanyl cannot be taken orally, the IR formulation of another opioid (e.g.: morphine, hydromorphone or oxycodone) is required for breakthroughs. An alternative approach is to use a parenteral formulation of fentanyl sublingually (especially if there is a significant incidental component to the pain). The dose is limited by the volume required. Volumes
4 4 of 5 exceeding ml are impractical. If the break-through dose requires a volume greater than 2 ml sublingually (parenteral formulation administered SL) then sufentanyl is an option. Calculate the dose of the breakthrough to be 10% of the total fentanyl daily dose (using the manufacturer s tables), eg: a 50 mcg/hour patch is equivalent to mg of oral morphine/24 hours. Morphine 20 mg po q l h prn would therefore be appropriate as a breakthrough order. Step 4: OVERLAP THE TD FENTANYL WITH THE PREVIOUS OPIOID FOR THE FIRST 12 HOURS When initiating the patch, it should be overlapped with the regular, IR opioid for the first 12 hours. (3 scheduled doses of the IR opioid) or one dose of a CR opioid, (i.e. q12h formulations and q24h formulations.) Step 5: Step 6: INITIAL TITRATION OF TD FENTANYL Because of its prolonged action, the transdermal fentanyl dose should only be increased every 3-6 days. Rely on the breakthrough doses to provide extra pain relief in the first 3 days. If more rapid titrations are necessary, they should be done under the guidance of a palliative care physician or pain specialist. THE PATCH SHOULD BE REPLACED EVERY 3 DAYS Rarely, do patients require patches replaced more frequently. Early wearing off of the patch can indicate under-dosing. Example of starting a patient on transdermal fentanyl: It is decided to switch a patient who has been stable on oral morphine 50 mg q4h to transdermal fentanyl. Step 1: Step 2: The total daily dose of morphine is, therefore, 300 mg po. According to the manufacturer s table, the equivalent dose of transdermal fentanyl is approximately 75 micrograms per hour. Rescue doses could be in the form of morphine 30 mg po q l h prn (10% of the total daily dose) or hydromorphone 6 mg q l h prn or oxycodone 15 mg po 1 h prn. The patch should be applied and the previous opioid formulation be continued for another twelve hours. After twelve hours the previous opioid is discontinued and the patient is left on the transdermal fentanyl and immediate release opioid for breakthroughs.
5 5 of 5 APPENDIX B: Table of equianalgesic doses of opioids Table 6: Equianalgesic dose Drug PO Dose PO:SC/IV Ratio SubCut/IV Dose Morphine 10 mg 2:1 5 mg Codeine 100 mg 2:1 50 mg Oxycodone * mg Hydromorphone 2 mg 2:1 1 mg Methadone 1 mg -- too irritating Fentanyl - infusion mcg Fentanyl patch use charts supplied by manufacturer in CPS morphine 10 mg po = codeine 100 mg po = oxycodone mg po = hydromorphone 2 mg po = methadone 1 mg po These tables are guidelines. There exist wide ranges in the dose ratio due to inter-individual variability in response to opioids. When switching opioids the doses should be decreased by a 25-30% and the patient should be monitored during the switch-over until they are stable. Methadone should be started and titrated under the guidance of a palliative care physician or pain specialist. Parenteral fentanyl should also be used under similar guidance. An interesting characteristic of the equianalgesic dose ratio of morphine and other opioids to methadone is that the ratio changes according to the dose of the previous opioid Alberta Health Services. This material is provided on an "as is", "where is" basis. Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use. * The equianalgesic dose ratio of morphine to oxycodone is controversial. It appears to be between 1.5:1 and 2:1 Many tables quote the equianalgesic dose ratio of morphine to methadone as being 1:1, i.e., morphine 1mg po = methadone 1 mg po. This ratio was determined using single dose studies. In cancer pain, when multiple doses are required, the ratio of morphine to methadone becomes approximately 10:1, i.e.,morphine 10 mg po = methadone 1 mg po. The equianalgesic dose ratio of morphine to fentanyl has not been accurately determined. It appears to be approximately 100:1, i.e., morphine 1 mg subcut = fentanyl 10 µ (micrograms) subcut. The equianalgesic ratio between parenteral fentanyl and transdermal fentanyl (patch) is also not well described, but appears to be approximately 1:1.
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117
More informationOpioid Conversion Guidelines
Opioid Conversion Guidelines March 2015 Gippsland Region Palliative Care Consortium Clinical Practice Group Title Keywords Ratified Opioid, Conversion, Drug, Therapy, Palliative, Guideline, Palliative,
More informationFighting the Good Fight: How to Convert Opioids Just Right!
Fighting the Good Fight: How to Convert Opioids Just Right! Tanya J. Uritsky, PharmD, BCPS, CPE Clinical Pharmacy Specialist - Pain Medication Stewardship Hospital of the University of Pennsylvania - Philadelphia,
More informationDose equivalent of fentanyl patch to oxycontin
Dose equivalent of fentanyl patch to oxycontin 10-3-2018 Detailed dosage guidelines and administration information for OxyContin (oxycodone hydrochloride). Includes dose adjustments, warnings and precautions.
More informationConversion chart from fentanyl to opana er
Conversion chart from fentanyl to opana er (e.g., Nucynta). Both opioid products involved in conversion are one of the following: morphine, oxycodone, oxymorphone, hydromorphone (not extended- release),
More informationOxycontin conversion to ms contin
Oxycontin conversion to ms contin The Borg System is 100 % Oxycontin conversion to ms contin Ms contin to morphine conversion MS Contin is. The patient s current dose of 240 mg per day of oral oxycodone
More informationOpioid Pearls and Acute Pain Management
Opioid Pearls and Acute Pain Management Jeanie Youngwerth, MD University of Colorado Denver Assistant Professor of Medicine, Hospitalist Associate Director, Colorado Palliative Medicine Fellowship Program
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationEquianalgesic Dosing: Making Opioid Interchange Easier. Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacist Assistant Professor Of Medicine
Equianalgesic Dosing: Making Opioid Interchange Easier Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacist Assistant Professor Of Medicine 1 Why Change Opioids? Side Effects Insufficient Pain
More informationOpioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.
Dose equivalence and switching between opioids Key Messages Switching from one opioid to another should only be recommended or supervised by a healthcare practitioner with adequate competence and sufficient
More informationNarcotic Equivalence Converter Narcotic Route Dose Duration; Select a drug: mg Convert to: mg Adapted from Tarascon Pocket Pharmacopoeia.
Narcotic Equivalence Converter Narcotic Route Dose Duration; Select a drug: mg Convert to: mg Adapted from Tarascon Pocket Pharmacopoeia. Created: Monday, March 12. Online calculator to convert equianalgesic
More informationFENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA
FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,
More informationFor patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.
Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative
More informationCanadian Expert Drug Advisory Committee Final Recommendation Plain Language Version
Canadian Expert Drug Advisory Committee Final Recommendation Plain Language Version BUPRENORPHINE TRANSDERMAL PATCH RESUBMISSION (BuTrans Purdue Pharma) Indication: Pain, Persistent (Moderate Intensity)
More informationNATL. II. Health Net Approved Indications and Usage Guidelines: Diagnosis of cancer AND. Member is on fentanyl transdermal patches AND
Coverage of drugs is first determined by the member s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document I. FDA Approved Indications: The management of breakthrough
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.CPA.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder
More informationMorphine er to oxycontin conversion
Morphine er to oxycontin conversion The Borg System is 100 % Morphine er to oxycontin conversion 17-4-2011 Conversion dose from Oxycontin 40mg 3x a day to morphine sulfate 15 mg?. Oxycontin vs morphine
More informationOpioid Conversion Ratios - Guide to Practice 2010
Opioid Conversion Ratios - Guide to Practice 2010 Released December 2010. 2010. The EMR PCC grants permission to reproduce parts of this publication for clinical and educational use only, provided that
More informationSupporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety
Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.HNMC.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationCare of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.
Care of the Dying Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance covers the prescribing and management of patients
More informationOpioid Conversions Mixture of Science and Art
Opioid Conversions Mixture of Science and Art Matthew J. Pingree, MD Assistant Professor Division of Pain Medicine Physical Medicine and Rehabilitation and Anesthesiology Mayo Clinic, Rochester Pingree.Matthew@Mayo.edu
More informationClinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid
Clinical Policy: Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationPAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose
NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,
More informationEducation Program for Prescribers and Pharmacists
Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under this Program Abstral (fentanyl)
More informationLimitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.21 Subject: Subsys Page: 1 of 5 Last Review Date March 17, 2017 Subsys Description Subsys (fentanyl
More informationAppendix 1. University of Minnesota Amplatz Children s Hospital Opioid Weaning Guideline
Appendix 1. University of Minnesota Amplatz Children s Hospital Opioid Weaning Guideline 1. Pharmacist to order Narcotic Withdrawal Scores QH X 4 hours, then per table below: Narcotic Withdrawal Score
More informationConvert hydrocodone to ms contin
Convert hydrocodone to ms contin The Borg System is 100 % Convert hydrocodone to ms contin Jan 29, 2018. HYDROcodone (Vicodin, Lortab), -, 30-45 mg, -, 3-5. OXYmorphone (Opana), 1 mg, 10 mg, 10:1, 3-6.
More informationGUIDELINES AND AUDIT IMPLEMENTATION NETWORK
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management
More informationTransdermal and Parenteral Fentanyl Dosage Calculations and Conversions
Transdermal and Parenteral Fentanyl Dosage Calculations and Conversions Chapter 5 Objectives After reading this chapter and completing all practice problems, the participant will be able to: 1. Describe
More informationPRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT
PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT A collaboration between: St. Rocco s Hospice, Bridgewater Community Healthcare NHS Trust, NHS Warrington Clinical Commissioning Group,
More informationQ&A: Opioid Prescribing for Chronic Non-Malignant Pain
NHS Hastings and Rother Clinical Commissioning Group Chair Dr David Warden Chief Officer Amanda Philpott NHS Eastbourne, Hailsham and Seaford Clinical Commissioning Group Chair Dr Martin Writer Chief Officer
More informationAnalgesics: Management of Pain In the Elderly Handout Package
Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain in the Elderly Each patient or resident and their pain problem is unique. A complete assessment should be performed
More informationAnalgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-
Page 1 of 8 Analgesia The World Health Organisation (WHO, 1990) has devised a model to assist health care professionals in the management of cancer pain. The recommendations include managing pain, by the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this policy
More informationCoversheet for Network Site Specific Group Agreed Documentation
Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance
More informationPALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST
PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST TREATMENT IN ONCOLOGY Main treatment : surgery Neoadjuvant treatment : RT, CMT Adjuvant treatment : Tx micrometastatic disease -CMT,Targeted
More informationORAL TRANSMUCOSAL AND NASAL FENTANYL UTILIZATION MANAGEMENT CRITERIA
ORAL TRANSMUCOSAL AND NASAL FENTANYL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: Fentanyl by oral transmucosal and nasal delivery Actiq (fentanyl citrate) lozenge on a handle 200,
More informationMid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care
Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage
More informationOpioid Case Studies. Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN. September 29, MFMER slide-1
Opioid Case Studies Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN September 29, 2016 2015 MFMER slide-1 Disclosures Relevant Financial Relationship(s) None Off Label and/or
More informationPharmacologic Considerations for Managing Sickle Cell Pain Claire Saadeh, PharmD, BCOP May 5, 2015
Pharmacologic Considerations for Managing Sickle Cell Pain Claire Saadeh, PharmD, BCOP May 5, 2015 Table 1: Physiologic changes that occur during sickle cell pain crisis 1-3 Phase Description / Complications
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Opioid Analgesics Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 11.17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the
More informationTHE EAPC OPIOID GUIDELINES: PROCESS, RESULTS AND FUTURE DEVELOPMENT
1 THE EAPC OPIOID GUIDELINES: PROCESS, RESULTS AND FUTURE DEVELOPMENT Jaegtvolden 4-5 June 2012 14. 12. 2012 2 1 3 WHO ANALGESIC LADDER (1996) NSAID +/- Adjuvant STEP II OPIODS Opids for mild to moderate
More informationPo dilaudid versus iv dilaudid
Po dilaudid versus iv dilaudid Search IM/IV/SC 120 mg ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic an equianalgesic ratio for PO. Dilaudid official prescribing
More informationNew Medicines Committee Briefing November 2011 Abstral (sublingual fentanyl citrate tablet) for the management of breakthrough cancer pain
New Medicines Committee Briefing November 2011 Abstral (sublingual fentanyl citrate tablet) for the management of breakthrough cancer pain Abstral is to be reviewed for use within: Primary Care Secondary
More informationFrom the Front Lines AlixaRx Clinical Pharmacists Address Everyday Challenges in Long-Term Care
April 2015 Issue From the Front Lines AlixaRx Clinical Pharmacists Address Everyday Challenges in Long-Term Care Therapeutic Interchange Recently AlixaRx announced the therapeutic interchange (TI) program
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 20 February 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 February 2008 DUROGESIC 12 micrograms/hour (2.1 mg/5.25 cm²), transdermal patch Box of 5 sachets (CIP: 369 851-5)
More informationOpioid Pain Management. John Manfredonia, DO. Disclosures. Dr. Manfredonia discloses his employment as Regional Medical Director for VistaCare
Opioid Pain Management John Manfredonia, DO Disclosures Dr. Manfredonia discloses his employment as Regional Medical Director for VistaCare VistaCare has provided commercial support for this activity Palliative
More informationPAIN MANAGEMENT Patient established on oral morphine or opioid naive.
PAIN MANAGEMENT Patient established on oral morphine or opioid naive. Important; It is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationHigh-Alert Medications: A Look at the Safe Use of Narcotics. Allen Vaida, BSc, PharmD Institute for Safe Medication Practices (ISMP)
High-Alert Medications: A Look at the Safe Use of Narcotics Allen Vaida, BSc, PharmD Institute for Safe Medication Practices (ISMP) Risk Identification in Healthcare The detection of a potential or actual
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationOxymorphone (Opana ) is indicated for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate.
Page 1 of 7 Policies Repository Policy Title Policy Number Schedule II Prior Authorization FS.CLIN.16 Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on
More informationPalliative Care Impact Survey
September 2018 Contents Introduction...3 Headlines...3 Approach...4 Findings...4 Which guideline are used...4 How and where the guidelines are used...6 Alternative sources of information...7 Use of the
More informationNBPDP Drug Utilization Review Process Update
Bulletin # 802 December 1, 2010 NBPDP Drug Utilization Review Process Update The New Brunswick Prescription Drug Program (NBPDP) employs a Drug Utilization Review (DUR) process which identifies, investigates
More informationSupportive Care. End of Life Phase
Supportive Care End of Life Phase Guidelines for Health Care Professionals In the care of patients with established renal failure who are in the last days of life References: Chambers E J (2004) End of
More informationE-Learning Module N: Pharmacological Review
E-Learning Module N: Pharmacological Review This Module requires the learner to have read Chapter 13 of the Fundamentals Program Guide and the other required readings associated with the topic. Revised:
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 6 Last Review Date: March 18, 2016 Duragesic patch Description Duragesic patch (fentanyl
More informationShining a Light on MEDs Understanding morphine equivalent dose
Shining a Light on MEDs Understanding morphine equivalent dose In the workers compensation industry, 60.2 percent of claimants utilize opioid analgesics for the treatment of pain caused by a workplace
More informationCare of the Dying Management in Severe Renal Failure
Care of the Dying Management in Severe Renal Failure Clinical Guideline Early recognition of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance
More information10 mg hydrocodone equals how much oxycodone
Cari untuk: Cari Cari 10 mg hydrocodone equals how much oxycodone Posts about dilaudid 8 vs oxycodone 30 written by buyprescriptionmedication. Can you help me with the conversion of Oxycodone IR (5mg tab)
More informationPrior Authorization Guideline
Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011
More informationCLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics
Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationCare of the Dying Management in Severe Renal Failure
Care of the Dying Management in Severe Renal Failure Clinical Guideline Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance
More informationSession II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids
Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be
More informationLong-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
More informationPAIN MANAGEMENT PGY-1. Aaron D. Storms, MD Carin van Zyl, MD Adult and Pediatric Palliative Care, LAC+USC Keck School of Medicine of USC
PAIN MANAGEMENT PGY-1 Aaron D. Storms, MD Carin van Zyl, MD Adult and Pediatric Palliative Care, LAC+USC Keck School of Medicine of USC Perception Matters A builder aged 29 came to the accident and emergency
More informationLong-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
More informationB. Long-acting/Extended-release Opioids
4 Opioid tolerance is assumed in patients already taking fentanyl 25 mcg/hr OR daily doses of the following oral agents for 1 week: 60 mg oral morphine, 30 mg oxycodone, 8 mg hydromorphone, 25 mg of oxymorphone
More informationPAIN MANAGEMENT Person established taking oral morphine or opioid naive.
PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationCLINICAL POLICY DEPARTMENT: Medical
IMPTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of currently available generally
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: LA.PPA.12 Effective Date: 02/11 Last Review Date: 01/18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy for
More informationConversion from oxycodone to ms contin
Search for: Search Search Conversion from oxycodone to ms contin Opioid Dose Converter. Enter 24-hour total doses below, then click the convert button to display 24-hour equianalgesic. Oxycodone SC. mg.
More information15mg oxycodone is equivalent to how much morphine
15mg oxycodone is equivalent to how much morphine The Borg System is 100 % 15mg oxycodone is equivalent to how much morphine nursing home activity director cover letter 15 mg oxycodone equal to how much
More informationBerkshire West Area Prescribing Committee Guidance
Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for
More informationOxycontin to ms contin conversion chart
Oxycontin to ms contin conversion chart The Pink, One-Piece Wrap Style 1 ( Pink Stripe) Size - Small - Medium - Large Length (neck to base of tail) - 10 inches - 14 inches - 20 inches Width (without side.
More informationOpioid Use in Serious Illness
Opioid Use in Serious Illness Jeanie Youngwerth, MD University of Colorado School of Medicine Associate Professor of Medicine, Hospitalist Director, Palliative Care Service Associate Director, Colorado
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Topic: fentanyl-containing medications: - Actiq, fentanyl citrate oral transmucosal lozenges - Abstral fentanyl sublingual tablets - Fentora, fentanyl buccal tablet - fentanyl
More informationNotice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for Fentanyl Transdermal Patch
Notice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for Fentanyl Transdermal Patch Frequently Asked Questions 1. What is the new Health Network System feature
More informationScottish Medicines Consortium
Scottish Medicines Consortium fentanyl 50 micrograms / dose, 100 micrograms/dose, 200 micrograms / dose nasal spray (Instanyl ) No. (579/09) Nycomed UK Ltd 09 October 2009 The Scottish Medicines Consortium
More informationClinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18
Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSCOPING DOCUMENT FOR WHO Treatment Guidelines on pain related to cancer, HIV and other progressive life-threatening illnesses in adults
SCOPING DOCUMENT FOR WHO Treatment Guidelines on pain related to cancer, HIV and other progressive life-threatening illnesses in adults BACKGROUND The justification for developing these guidelines lies
More informationGUIDELINES FOR CONVERSION FROM A STRONG OPIOID TO METHADONE
GUIDELINES FOR CONVERSION FROM A STRONG OPIOID TO METHADONE GENERAL PRINCIPLES Methadone may be used as a strong opioid alternative when severe cancer-related pain responds poorly to other opioids, or
More informationClinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19
Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationGUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT (estimated glomerular filtration rate<30)
GUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT These guidelines have been produced in collaboration with Dr Lucy Smyth, Consultant in Renal Medicine, Royal Devon and Exeter
More informationANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT
ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL Doses of opiates must be proptional to current analgesic medication Please refer ALL patients on Methadone Ketamine to SPCT f advice. Patients
More information4/3/2018. Management of Acute Pain Crises. Five Mistakes I ve made and why you shouldn t
Management of Acute Pain Crises Maggie O Connor, M.D. Retired Palliative Care Physician Hope is not the conviction that something will turn out well, but the certainty that something makes sense, regardless
More informationPolicy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04
Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical
More informationEnd of life prescribing guidance
End of life prescribing guidance Introduction This guidance has been prepared to ASSIST IN DECISION MAKING for the prescribing and monitoring of medicines useful in the management of symptoms commonly
More informationSTARSHIP WITHDRAWAL OF ANALGESIA AND SEDATION
STARSHIP WITHDRAWAL OF ANALGESIA AND SEDATION Patients receiving analgesia and/or sedation for longer than 5-7 days may suffer withdrawal if these drugs are suddenly stopped. To prevent this happening
More informationDrug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans
FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics 7/9/2012 Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA
More informationGuidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth)
Guidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth) Policy Number : DC020 Issue Date: October 2014 Review date: October 2016 Policy Owner: Head Community Services Monitor:
More informationPharmacy Medical Necessity Guidelines: Opioid Analgesics
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationAmber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center
Pharmacologic Management of Pain Amber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center Objectives Identify types of
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Transmucosal Fentanyl Effective Date... 4/15/2018 Next Review Date... 4/15/2019 Coverage Policy Number... 1018 Table of Contents Coverage Policy... 1 General
More informationPalliative Prescribing - Pain
Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing
More informationAETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as
More informationInterprofessional Webinar Series
Interprofessional Webinar Series Opioids in the Medically Ill: Principles of Administration Russell K. Portenoy, MD Chief Medical Officer MJHS Hospice and Palliative Care Director MJHS Institute for Innovation
More informationBree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationSymptom Management Guidelines for End of Life Care
Symptom Management Guidelines for End of Life Care The following pages are guidelines for the management of common symptoms in the last few days of life. General principles: 1. Consider how symptoms can
More information